There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

The cancer transcriptome is remarkably complex, including low-abundance transcripts, many
not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we …

Background Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable
subpathologies in localized prostate cancer. We recently showed that IDC shares a …

BACKGROUND: The clinical significance of tumor-infiltrating dendritic cells (TIDCs) and
tumor-associated macrophages (TAMs) as markers of immune response has been reported for …

A simple phase-characterization method for spatial light modulators is proposed. The low-cost
method permits high-precision measurement and provides data for the setting of the …

The identification of biomarker signatures in omics molecular profiling is usually performed
to predict outcomes in a precision medicine context, such as patient disease susceptibility, …

Cancer‐testis (CT) genes encode proteins that are ideal targets for cancer immunotherapy
because of their restricted expression in normal tissues and frequent expression in cancers. …

Toll-like receptors (TLRs) have an important role in the activation of both innate and adaptive
immunity in response to pathogens and danger signals. These receptors are expressed in …

MUC1 is a glycoprotein expressed on the apical surface of ductal epithelial cells. Malignant
transformation results in loss of polarization and overexpression of hypoglycosylated MUC1 …